A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Lyell Immunopharma, Inc.
Therapeutic Advances in Childhood Leukemia Consortium
Beijing Biotech
Gilead Sciences
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Beijing Biotech
Artiva Biotherapeutics, Inc.
M.D. Anderson Cancer Center
AvenCell Therapeutics, Inc.
Daiichi Sankyo
H. Lee Moffitt Cancer Center and Research Institute
Beijing Biotech
Beijing Biotech
Medical University of South Carolina
National Institutes of Health Clinical Center (CC)
Beijing Biotech
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Beijing Biotech
Chinese PLA General Hospital
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Allogene Therapeutics
National Institutes of Health Clinical Center (CC)
Intima Bioscience, Inc.
Intima Bioscience, Inc.
UNC Lineberger Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Essen Biotech
Fred Hutchinson Cancer Center
Dana-Farber Cancer Institute
Washington University School of Medicine
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
TCRCure Biopharma Ltd.
Xinqiao Hospital of Chongqing
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
Astellas Pharma Inc
National Institutes of Health Clinical Center (CC)
Changhai Hospital
M.D. Anderson Cancer Center